2024 ICD-10-CM Diagnosis Code T45.1X5S
Adverse effect of antineoplastic and immunosuppressive drugs, sequela
- ICD-10-CM Code:
- T45.1X5S
- ICD-10 Code for:
- Adverse effect of antineopl and immunosup drugs, sequela
- Is Billable?
- Yes - Valid for Submission
- Chronic Condition Indicator: [1]
- Not chronic
- Code Navigator:
- Code Information
- Approximate Synonyms
- Clinical Classification
- Clinical Information
- Coding Guidelines
- Tabular List of Diseases and Injuries
- Code Edits
- Diagnostic Related Groups Mapping
- Present on Admission (POA)
- Convert to ICD-9 Code
- Table of Drugs and Chemicals
- Patient Education
- Other Codes Used Similar Conditions
- Code History
T45.1X5S is a billable diagnosis code used to specify a medical diagnosis of adverse effect of antineoplastic and immunosuppressive drugs, sequela. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.
This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
T45.1X5S is a sequela code, includes a 7th character and should be used for complications that arise as a direct result of a condition like adverse effect of antineoplastic and immunosuppressive drugs. According to ICD-10-CM Guidelines a "sequela" code should be used for chronic or residual conditions that are complications of an initial acute disease, illness or injury. The most common sequela is pain. Usually, two diagnosis codes are needed when reporting sequela. The first code describes the nature of the sequela while the second code describes the sequela or late effect.
Approximate Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Accelerated rheumatoid nodulosis
- Accelerated rheumatoid nodulosis caused by methotrexate
- Aclarubicin adverse reaction
- Acral erythema due to cytotoxic therapy
- Acute myeloid leukemia and myelodysplastic syndrome related to alkylating agent
- Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor
- Acute promyelocytic leukemia, FAB M3
- Adverse reaction to antineoplastic antibiotics
- Adverse reaction to dimethyl sulfoxide and/or idoxuridine
- Adverse reaction to rituximab administered by infusion
- Adverse reaction to sarilumab
- Adverse reaction to trastuzumab administered by infusion
- Adverse reaction to triazene
- Agranulocytosis
- Agranulocytosis due to and following administration of antineoplastic agent
- Aldesleukin adverse reaction
- Alkylating drug adverse reaction
- Amifostine adverse reaction
- Amsacrine adverse reaction
- Anemia caused by antineoplastic agent
- Antimetabolite adverse reaction
- Antineoplastic adverse reaction
- Aplastic anemia caused by antineoplastic agent
- Aplastic anemia due to drugs
- Azathioprine adverse reaction
- Azoospermia caused by chemotherapy
- Bleomycin adverse reaction
- Busulfan adverse reaction
- Carboplatin adverse reaction
- Cardiomyopathy caused by drug
- Carmustine adverse reaction
- Cellular atypia due to antineoplastic agent
- Chlorambucil adverse reaction
- Chlormethine adverse reaction
- Chronic cyclosporin A nephrotoxicity
- Chronic drug-induced renal disease
- Chronic drug-induced renal disease
- Chronic drug-induced renal disease
- Chronic painful polyneuropathy following chemotherapy
- Chronic peripheral neuropathic pain
- Cirrhosis of liver caused by methotrexate
- Cisplatin adverse reaction
- Cis-platinum nephropathy
- Complication of chemotherapy
- Crisantaspase adverse reaction
- Cyclophosphamide adverse reaction
- Cyclosporin adverse reaction
- Cytarabine adverse reaction
- Cytotoxic antibiotic adverse reaction
- Dacarbazine adverse reaction
- Dactinomycin adverse reaction
- Dermatosis caused by immunosuppressant
- Dermatosis resulting from cytotoxic therapy
- Differentiation syndrome due to and following chemotherapy co-occurrent with acute promyelocytic leukemia
- Dilated cardiomyopathy caused by anthracycline
- Dilated cardiomyopathy secondary to drug
- Dimethyl sulfoxide adverse reaction
- Disorder of skin caused by epidermal growth factor receptor inhibitor
- Doxorubicin adverse reaction
- Drug-induced cirrhosis of liver
- Drug-induced immunodeficiency
- Drug-induced tubulointerstitial nephritis
- Epirubicin adverse reaction
- Esophagitis due to chemotherapy
- Estramustine adverse reaction
- Ethoglucid adverse reaction
- Etoposide adverse reaction
- Fatigue due to chemotherapy
- Fludarabine adverse reaction
- Fluorouracil adverse reaction
- Gonad regulating hormone adverse reaction
- Gonad regulating hormone adverse reaction
- Gonad regulating hormone adverse reaction
- Goserelin adverse reaction
- Growing teratoma syndrome
- Hematologic complication of procedure
- Hematologic complication of procedure
- Hematologic complication of procedure
- Hematologic complication of procedure
- Hydroxycarbamide adverse reaction
- Iatrogenic immunodeficiency-associated lymphoproliferative disorder
- Idarubicin adverse reaction
- Ifosfamide adverse reaction
- Immunodeficiency secondary to chemotherapy
- Immunosuppressant adverse reaction
- Inflammation of mucous membrane due to and following chemotherapy
- Leuprorelin adverse reaction
- Lomustine adverse reaction
- Lymphoproliferative disorder caused by methotrexate
- Malignant neoplasm after immunosuppressive therapy
- Melphalan adverse reaction
- Mercaptopurine adverse reaction
- Methotrexate adverse reaction
- Methotrexate poisoning
- Methotrexate skin ulceration
- Methyl CCNU nephropathy
- Mitobronitol adverse reaction
- Mitomycin adverse reaction
- Mitoxantrone adverse reaction
- Myelopathy post intrathecal injection of chemotherapeutic agent
- Myelosuppression
- Myelosuppression due to chemotherapy
- Neoplastic complication of procedure
- Neoplastic complication of procedure
- Neoplastic complication of procedure
- Neoplastic complication of procedure
- Nephritis caused by drug
- Nephropathy induced by cyclosporine
- Nephropathy induced by tacrolimus
- Neurological pain disorder
- Neurotoxicity due to L-asparaginase
- Neurotoxicity due to methotrexate
- Neurotoxicity due to procarbazine
- Neurotoxicity due to vinblastine
- Neurotoxicity due to vincristine
- Nitrogen mustard derivative adverse reaction
- Nitrosurea adverse reaction
- Paclitaxel adverse reaction
- Palmar erythema
- Pancytopenia caused by immunosuppressant
- Pancytopenia caused by medication
- Pancytopenia caused by medication
- Pancytopenia due to antineoplastic chemotherapy
- Pentostatin adverse reaction
- Peripheral neuropathic pain
- Peripheral neuropathy due to and following antineoplastic therapy
- Plicamycin adverse reaction
- Poisoning by L-asparaginase
- Post-immunosuppression viral warts
- Procarbazine adverse reaction
- Procarbazine poisoning
- Razoxane adverse reaction
- Retinoid adverse reaction
- Rheumatoid nodule
- Ruxolitinib withdrawal
- Secondary aplastic anemia
- Stomatitis due to cytotoxic therapy
- Stomatitis medicamentosa
- Stomatitis medicamentosa
- Subcutaneous rheumatoid nodule
- Terpenes adverse reaction
- Terpenes adverse reaction
- Therapy related acute myeloid leukemia due to and following administration of antineoplastic agent
- Therapy related acute myeloid leukemia due to and following administration of antineoplastic agent
- Therapy-related myelodysplastic syndrome
- Therapy-related myelodysplastic syndrome
- Therapy-related myelodysplastic syndrome
- Thioguanine adverse reaction
- Thiotepa adverse reaction
- Thrombophilia due to antineoplastic agent therapy
- Thrombophilia due to drug therapy
- Treosulfan adverse reaction
- Triptorelin adverse reaction
- Ulcerative inflammation of oral mucous membrane due to and following administration of antineoplastic agent
- Ulcerative stomatitis
- Vinblastine adverse reaction
- Vinblastine poisoning
- Vinca alkaloid adverse reaction
- Vincristine adverse reaction
- Vincristine poisoning
- Vindesine adverse reaction
- Warts in immune-deficient state
Clinical Classification
Clinical Category is Poisoning/toxic effect/adverse effects/underdosing, sequela
- CCSR Category Code: INJ075
- Inpatient Default CCSR: X - Not applicable.
- Outpatient Default CCSR: Y - Yes, default outpatient assignment for principal diagnosis or first-listed diagnosis.
Clinical Information
Agranulocytosis
a decrease in the number of granulocytes; (basophils; eosinophils; and neutrophils).Feline Panleukopenia
a highly contagious dna virus infection of the cat family, characterized by fever, enteritis and bone marrow changes. it is also called feline ataxia, feline agranulocytosis, feline infectious enteritis, cat fever, cat plague, and show fever. it is caused by feline panleukopenia virus or the closely related mink enteritis virus or canine parvovirus.Rheumatoid Nodule
subcutaneous nodules seen in 20-30% of rheumatoid arthritis patients. they may arise anywhere on the body, but are most frequently found over the bony prominences. the nodules are characterized histologically by dense areas of fibrinoid necrosis with basophilic streaks and granules, surrounded by a palisade of cells, mainly fibroblasts and histiocytes.Agranulocytosis
a marked decrease in the number of mature granulocytes (most often neutrophils) in the peripheral blood.Chemotherapy Related Agranulocytosis|Chemotherapy-Related Agranulocytosis
agranulocytosis that occurs with chemotherapy.Congenital Neutropenia|congenital neutropenia|genetic infantile agranulocytosis|infantile genetic agranulocytosis
a rare congenital disorder characterized by mild or severe reduction of neutrophils in the peripheral blood and recurrent infantile infections.Cyclic Neutropenia|CH|CN|Cyclic Agranulocytosis|Cyclic Hematopoiesis|Cyclic Hematopoiesis|Dysplasia, Myelocytic Periodic|Periodic Neutropenia|cyclic neutropenia|periodic neutropenia
a hematologic disorder caused by a mutation in the elane (ela2) gene; clinical manifestations include recurrent neutropenia with resultant susceptibility to infection leading to fever.Tumor Protein 63|CUSP|Chronic Ulcerative Stomatitis Protein|Keratinocyte Transcription Factor KET|TP63|Transformation-Related Protein 63|Tumor Protein p73-Like|p40|p51|p63|p73L
tumor protein 63 (680 aa, ~77 kda) is encoded by the human tp63 gene. this protein plays a role in the mediation of both transcription and limb morphogenesis.Ulcerative Stomatitis
inflammation of the mouth mucosa associated with the presence of ulcers.
Coding Guidelines
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45). Use the following options for the aplicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:
- Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.
Present on Admission (POA)
T45.1X5S is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.
CMS POA Indicator Options and Definitions
POA Indicator | Reason for Code | CMS will pay the CC/MCC DRG? |
---|---|---|
Y | Diagnosis was present at time of inpatient admission. | YES |
N | Diagnosis was not present at time of inpatient admission. | NO |
U | Documentation insufficient to determine if the condition was present at the time of inpatient admission. | NO |
W | Clinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission. | YES |
1 | Unreported/Not used - Exempt from POA reporting. | NO |
Convert T45.1X5S to ICD-9-CM
- ICD-9-CM Code: 909.5 - Lte efct advrs efct drug
Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment. - ICD-9-CM Code: E933.1 - Adv eff antineoplastic
Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.
Table of Drugs and Chemicals
The parent code T45.1X5 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.
According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.
Patient Education
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
What is a drug interaction?
A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:
- Two drugs, such as aspirin and blood thinners
- Drugs and food, such as statins and grapefruit
- Drugs and supplements, such as gingko and blood thinners
- Drugs and medical conditions, such as aspirin and peptic ulcers
Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.
What are side effects?
Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.
What are drug allergies?
Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.
How can I stay safe when taking medicines?
When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.
[Learn More in MedlinePlus]
Code History
- FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
- FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
- FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.